Pieris Pharmaceuticals to Present at Investor Conferences in November
08 Novembre 2018 - 2:00PM
Pieris Pharmaceuticals, Inc. (NASDAQ: PIRS), a
clinical-stage biotechnology company advancing novel
biotherapeutics through its proprietary Anticalin® technology
platform for cancer, respiratory and other diseases, announced
today that members of the management team will present at the
following investor conferences in November:
Jefferies London Healthcare
ConferenceThursday, November 15, 2018 at 9:20AM GMT at the
Waldorf Hilton (Aldwych) Hotel in London. A webcast of the
Company’s presentation will be available at this link.
Evercore ISI
HealthconXWednesday, November 28, 2018 at 12:50PM EST at
the Boston Harbor Hotel in Boston. A webcast of the Company’s
presentation will be available at this link.
About Pieris Pharmaceuticals
Pieris is a clinical-stage biotechnology company that discovers and
develops Anticalin protein-based drugs to target validated disease
pathways in a unique and transformative way. Our pipeline includes
immuno-oncology multi-specifics tailored for the tumor
microenvironment, an inhaled Anticalin protein to treat
uncontrolled asthma and a half-life-optimized Anticalin protein to
treat anemia. Proprietary to Pieris, Anticalin proteins are a novel
class of therapeutics validated in the clinic and by partnerships
with leading pharmaceutical companies. Anticalin® is a registered
trademark of Pieris. For more information, visit
www.pieris.com.
Forward Looking Statements This
press release contains forward-looking statements as that term is
defined in Section 27A of the Securities Act of 1933 and Section
21E of the Securities Exchange Act of 1934. Statements in this
press release that are not purely historical are forward-looking
statements. Such forward-looking statements include, among other
things, references to novel technologies and methods and our
business and product development plans, including the advancement
of our proprietary and co-development programs into and through the
clinic. Actual results could differ from those projected in any
forward-looking statements due to numerous factors. Such factors
include, among others, our ability to raise the additional funding
we will need to continue to pursue our business and product
development plans; the inherent uncertainties associated with
developing new products or technologies and operating as a
development stage company; our ability to develop, complete
clinical trials for, obtain approvals for and commercialize any of
our product candidates, including our ability to recruit and enroll
patients in our studies; our ability to address the requests of the
FDA; competition in the industry in which we operate and market
conditions. These forward-looking statements are made as of the
date of this press release, and we assume no obligation to update
the forward-looking statements, or to update the reasons why actual
results could differ from those projected in the forward-looking
statements, except as required by law. Investors should consult all
of the information set forth herein and should also refer to the
risk factor disclosure set forth in the reports and other documents
we file with the SEC available at www.sec.gov, including without
limitation the Company's Annual Report on Form 10-K for the fiscal
year ended December 31, 2017 and the Company's Quarterly Reports on
Form 10-Q.
Company Contact: Allan Reine SVP & Chief
Financial Officer +1 857 444 4276 reine@pieris.com
Investor Relations Contact: Maria Kelman Director, Investor
Relations +1 857 362 9635 kelman@pieris.com
Grafico Azioni Pieris Pharmaceuticals (NASDAQ:PIRS)
Storico
Da Mag 2024 a Giu 2024
Grafico Azioni Pieris Pharmaceuticals (NASDAQ:PIRS)
Storico
Da Giu 2023 a Giu 2024